



Problem Solving in Cancer and Fertility

ELENI M KARAPANAGIOTOU,
JULIA KOPEIKA, RUTH E BOARD,
CAROLINE ARCHER, MELANIE C DAVIES,
JANINE MANSI

Published in association
with the Association of
Cancer Physicians

ebn.
health

Problem Solving in Cancer and Fertility

Problem Solving in Cancer and Fertility

Edited by

Eleni M Karapanagiotou, MD, PhD

Consultant Medical Oncologist, Guy's Cancer Centre, Guy's and St Thomas'
NHS Foundation Trust, London, UK

Julia Kopeika, MD, MRCOG, PhD

Consultant Gynaecologist and Subspecialist in Reproductive Medicine and Surgery,
Assisted Conception Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK

Ruth E Board, BSc, MBChB, PhD, FRCP

Consultant in Medical Oncology, Rosemere Cancer Centre, Royal Preston Hospital,
Preston, UK

Caroline Archer, BSc, MBBS, FRCP

Consultant Medical Oncologist, Portsmouth Oncology Centre, Portsmouth Hospitals
University NHS Trust, Portsmouth, UK

Melanie C Davies, MBBS, MA, MRCP, FRCOG

Consultant Gynaecologist, Reproductive Medicine Unit, University College London
Hospitals, London, UK

Janine Mansi, MD, FRCP, FACP(UK)

Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust and
Biomedical Research Centre, King's College London, UK

Published in association with the Association of Cancer Physicians

EBN HEALTH

OXFORD, UK

EBN Health
An imprint of Evidence-based Networks Ltd
85 Newland
Witney, Oxfordshire OX28 3JW, UK

Tel: +44 1865 522326
Email: info@ebnhealth.com

Web: www.ebnhealth.com

Distributed worldwide by:
Marston Book Services Ltd
160 Eastern Avenue
Milton Park
Abingdon
Oxon OX14 4SB, UK
Tel: +44 1235 465500
Fax: +44 1235 465555
Email: trade.orders@marston.co.uk

© Evidence-based Networks Ltd 2021

First edition published 2021

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from EBN Health or Evidence-based Networks Ltd.

Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to the attention in writing of EBN Health or Evidence-based Networks Ltd.

EBN Health and Evidence-based Networks Ltd bear no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and do not guarantee that any content on such websites is, or will remain, accurate or appropriate.

A catalogue record for this book is available from the British Library.

ISBN 13 978 0 99559 546 0

The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publisher do not accept any liability for any errors in the text or for the misuse or misapplication of material in this work.

Series design by Pete Russell Typographic Design, Faringdon, Oxon, UK
Typeset by Thomson Digital, Noida, India
Printed by Hobbs the Printers Ltd, Totton, Hampshire, UK

Contents

Contributors	viii
Preface	xiii
Acknowledgements	xv
SECTION ONE Perspectives	
01 The Effects of Cancer and its Treatment on Female Fertility, <i>Richard A. Anderson</i>	1
02 Fertility Preservation in Women, <i>Julia Kopeika</i>	7
03 Fertility Preservation in Men, <i>Maj Shabbir</i>	12
04 Management of Cancer in Pregnancy, <i>Kate Harding</i>	19
05 Drugs Used to Treat Cancer During Pregnancy, <i>Alison L. Jones, Ruth E. Board</i>	24
06 Pregnancy After Diagnosis and Treatment of Cancer, <i>Danielle Crawley, Eleni M. Karapanagiotou</i>	30
07 Fertility Outcome in Men After Cancer Treatment, <i>Allan Pacey</i>	34
08 Premature Ovarian Insufficiency—Diagnosis and Overview of Survivorship Issues, <i>Melanie C. Davies</i>	38
09 Egg Donation and Surrogacy, <i>Mari Isdale, Raj Mathur</i>	43
10 Hormone Replacement Options for Women with Premature Ovarian Insufficiency After Cancer Treatments, <i>Lisa Webber</i>	50
11 Hereditary Cancer Syndromes and Fertility, <i>Annabelle Kerr, Charlotte Tomlinson, Vishakha Tripathi</i>	55
12 Counselling—Cancer and Fertility: What Does a Counsellor in a Fertility Clinic Do?, <i>Carmel Dennehy</i>	60
13 Ethical Issues in Fertility Preservation for Cancer Patients, <i>Francoise Shenfield</i>	65
SECTION TWO Case Studies	
01 Fertility Preservation in Early Breast Cancer, <i>Chara Stavrou, Julia Kopeika</i>	69
02 Fertility Preservation in Cervical Cancer, <i>Jonathan Riley, Nicholas Wood</i>	73

03	Fertility Preservation in Testicular Cancer, <i>Majed Shabbir, Neerujah Balachandren</i>	78
04	Post-Partum Fertility Preservation, <i>Lukasz Polanski, Julia Kopeika</i>	82
05	Colon Cancer With Inherited Genetics: Lynch Syndrome, <i>Christopher Williams, Jenny Seligmann</i>	87
06	Ovarian Tissue Cryopreservation in the Setting of Recurrent Cancer and Escalation of Treatment, <i>Dalia Khalife, Julia Kopeika</i>	92
07	Fertility Preservation in a Young Man Unable to Produce a Sperm Sample, <i>Saira Khalique, Philippa Sangster</i>	99
08	A Case of an Unexpected Conception in a Patient With Metastatic Melanoma on Immune Checkpoint Inhibitors, <i>Prerana Huddar, Ruth Board</i>	105
09	An Unexpected Pregnancy in a Woman With Metastatic Breast Cancer, <i>Rachel Broadbent, Alia Alchawaf, Laura Horsley</i>	111
10	Accidental Pregnancy During Chemotherapy Treatment, <i>Sarah Hunter, Catherine Oakley, Eleni Karapanagiotou</i>	115
11	A Case of Lung Cancer Diagnosed During Pregnancy, <i>Alexandra R. Lewis, Catherine Nelson-Piercy</i>	119
12	A Woman Who Wishes to Become Pregnant Following Treatment for ER+ Breast Cancer, <i>Joanna Hack, Eleni M. Karapanagiotou</i>	123
13	Pregnancy After Bone Marrow Transplant, <i>Helen Hockings, Melanie C. Davies</i>	126
14	Woman With Premature Ovarian Insufficiency After Stem Cell Transplant and Total Body Irradiation Seeking Fertility Treatment, <i>Guy Morris, Melanie C. Davies</i>	132
15	Premature Ovarian Insufficiency, HRT and VTE, <i>Meera Chauhan, Sean Dulloo, Oyeyemi Akala, Mari Thomas</i>	137
16	Premature Ovarian Insufficiency and HRT in Breast Cancer: Management of Vaginal Symptoms and Hot Flashes, <i>Kathryn Herring, Daniel Rea</i>	141
17	Premature Ovarian Insufficiency and Bone Health, <i>Emily Goode, Janine Mansi</i>	146
18	Pregnancy After Testicular Failure Caused by Cancer Treatment, <i>Sofia Nyberg, Maj Shabbir, Julia Kopeika</i>	152
19	Risk Reducing Bilateral Salpingo-Oophorectomy in BRCA Positive Breast Cancer, <i>Kathryn Baxter, Nick Wood, Sarah Moon</i>	157
20	A Case of a Pregnancy Following Radical Trachelectomy, <i>Yusuf Beebeejaun, Julia Kopeika</i>	162

21	A Case of Ovarian Tissue Cryopreservation in the Setting of Non-Hodgkin's Lymphoma, <i>Dalia Khalife, Julia Kopeika</i>	167
22	A Case of Breast Cancer in a Transgender Man With BRCA2 Mutation, <i>Alison Berner, Leighton Seal, Katie Snape</i>	172
23	A Case of Testicular Cancer in a Gay Man, <i>Alison Berner, Daniel Hughes, Daniel Saunders</i>	177
	Index	181

Contributors

- Dr Oyeyemi Akala**, Medical Oncology Specialist Registrar, University Hospitals of Leicester NHS Trust, Leicester
oyeyemi.akala@nhs.net
- Dr Alia Alchawaf**, Specialist Registrar in Medical Oncology, The Christie NHS Foundation Trust, Manchester
aliaalchawaf@nhs.net
- Professor Richard A Anderson**, Elsie Inglis Professor of Clinical Reproductive Science, MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh
richard.anderson@ed.ac.uk
- Dr Neerujah Balachandren**, Clinical Research Fellow in Reproductive Medicine, University College London Hospital, London
n.balachandren@nhs.net
- Dr Kathryn Baxter**, Obstetric and Gynaecology Specialist Trainee, Lancashire Teaching Hospitals NHS Foundation Trust, Preston
kbaxter@doctors.org.uk
- Dr Yusuf Beebeejaun**, Clinical Research Fellow, King's Fertility, King's College Hospital, London
Yusufb1@gmail.com
- Dr Alison Berner**, Speciality Trainee and Clinical Research Fellow in Medical Oncology, Barts Cancer Institute and Specialist Registrar in Gender Identity, Tavistock and Portman NHS Foundation Trust, London
alisonmayberner@gmail.com
- Dr Ruth E Board**, Consultant in Medical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston
Ruth.Board@LTHTR.nhs.uk
- Dr Rachel Broadbent**, Specialist Registrar in Medical Oncology, The Christie NHS Foundation Trust, Manchester
rachel.broadbent-2@postgrad.manchester.ac.uk
- Dr Meera Chauhan**, Medical Oncology Specialist Registrar, University Hospitals of Leicester NHS Trust
Meera.chauhan@doctors.org.uk
- Dr Danielle Crawley**, Specialist Registrar Medical Oncology, Guy's and St Thomas NHS Foundation Trust, London
Danielle.Crawley@gstt.nhs.uk
- Dr Melanie C Davies**, Consultant Gynaecologist, Reproductive Medicine Unit, University College London Hospitals, London
melanie.davies14@nhs.net

- Carmel Dennehy**, Specialist Counsellor and Psychotherapist in Reproductive Medicine, University College London Hospital, London
carmel.dennehy@nhs.net
- Dr Sean Dullo**, Medical Oncology Specialist Registrar, University Hospitals of Leicester NHS Trust, Leicester
seandullo@doctors.org.uk
- Dr Emily Goode**, Specialist Registrar Medical Oncology, The Royal Marsden Hospital, London
efgoode@gmail.com
- Dr Joanna Hack**, Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton
joanna.hack@doctors.org.uk
- Dr Kate Harding**, Consultant Obstetrician, Guy's and St Thomas' Foundation Trust, London
Kate.harding@gstt.nhs.uk
- Dr Kathryn Herring**, SpR Medical Oncology, Queen Elizabeth Hospital, Edgbaston, Birmingham
Katy.Herring@uhb.nhs.uk
- Dr Helen Hockings**, Medical Oncology Specialist Registrar, St Bartholomew's Hospital, London
hahockings@gmail.com
- Dr Laura Horsley**, Consultant Medical Oncologist, The Christie NHS Foundation Trust, Manchester.
Laura.Horsley@christie.nhs.uk
- Dr Prerana Huddar**, ST3 Medical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston
prerana.huddar@lthtr.nhs.uk
- Dr Daniel Johnathan Hughes**, Specialist Registrar in Medical Oncology, UCL Cancer Institute, University College, London
daniel.hughes@kcl.ac.uk
- Dr Sarah Hunter**, Medical Oncology Registrar, Guy's and St Thomas' Hospital, London
Sarah.hunter@gstt.nhs.uk
- Dr Mari Isdale**, Senior Clinical Fellow IVF and Reproductive Medicine, Manchester Foundation Trust, Manchester
mariisdale@gmail.com
- Dr Alison Jones**, Consultant Medical Oncologist, The Royal Free London NHS Foundation Trust, London
ajones@theloc.com
- Dr Eleni M Karapanagiotou**, Consultant Medical Oncologist, Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London
Eleni.Karapanagiotou@gstt.nhs.uk

- Annabelle Kerr**, Genetic Counsellor, Clinical Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London
annabelle.kerr@gstt.nhs.uk
- Dr Dalia Khalife**, Specialist in Obstetrics and Gynecology, Subspecialist in Reproductive Endocrinology and Infertility, Jumeirah American Clinic, Dubai, United Arab Emirates
khalifehdalia@gmail.com
- Dr Saira Khalique**, Speciality Registrar in Medical Oncology, University College London Hospitals NHS Foundation Trust, London
saira.khalique1@nhs.net
- Dr Julia Kopeika**, Consultant Gynaecologist and Subspecialist in Reproductive Medicine and Surgery, Assisted Conception Unit, Guy's & St Thomas' NHS Foundation Trust, London
Yuliya.Kopeika@gstt.nhs.uk
- Dr Alexandra R Lewis**, Clinical Fellow, Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester
Alexandra.lewis@christie.nhs.uk
- Dr Janine Mansi**, Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London
Janine.Mansi@gstt.nhs.uk
- Dr Raj Mathur**, Consultant in Reproductive Medicine and Surgery, Manchester University NHS Foundation Trust.
rmathur@nhs.net
- Dr Sarah Moon**, Consultant Oncologist, University Hospitals of Morecambe Bay
Sarah.moon@mhbt.nhs.uk
- Dr Guy Morris**, Clinical Fellow in Reproductive Medicine, Reproductive Medicine Unit, Elizabeth Garrett Anderson Hospital, University College London Hospitals, London
guy.morris1@nhs.net
- Professor Cathy Nelson-Piercy**, Consultant Obstetric Physician, Guy's & St Thomas' Foundation Trust, London
Catherine.Nelson-Piercy@gstt.nhs.uk
- Dr Sofia Nyberg**, Guy's and St Thomas' Medical School, King's College London
sofia.nyberg@kcl.ac.uk
- Dr Catherine Oakley**, Chemotherapy Consultant Nurse, Guy's and St Thomas' NHS Foundation Trust, London
Catherine.Oakley@gstt.nhs.uk
- Professor Allan Pacey**, Professor of Andrology, University of Sheffield, Sheffield
a.pacey@sheffield.ac.uk
- Dr Lukasz Polanski**, Subspecialty Trainee in Reproductive Medicine and Surgery, Assisted Conception Unit, Guy's Hospital, London
Lukasz.Polanski@gstt.nhs.uk

- Professor Daniel Rea**, Professor of Medical Oncology, University of Birmingham
d.w.rea@icloud.com
- Dr Jonathan Riley**, Specialty Registrar in Obstetrics & Gynaecology, Sharoe Green Unit, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust
jonathan.riley@doctors.org.uk
- Miss Pippa Sangster**, Consultant Urological Surgeon and Andrologist, Clinical Lead for Male Infertility, University College London Hospital NHS Foundation Trust
philippa.sangster@nhs.net
- Dr Daniel Saunders**, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester
Daniel.Saunders@christie.nhs.uk
- Dr Leighton Seal**, The Tavistock and Portman NHS Foundation Trust, London and St George's University Hospitals NHS Foundation Trust, London
lseal@sgul.ac.uk
- Dr Jenny Seligmann**, Senior Lecturer and Consultant Medical Oncologist, Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
j.seligmann@nhs.net
- Mr Majed Shabbir**, Consultant Urological Surgeon, Guy's & St. Thomas' Hospital, London
Majed.Shabbir@gstt.nhs.uk
- Dr Françoise Shenfield**, Clinical Lecturer in Infertility, Reproductive Medicine Unit, University College London Hospitals, London
francoise.shenfield@nhs.net
- Dr Katie Snape**, Consultant Cancer Geneticist, South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London.
Katie.snape@stgeorges.nhs.uk
- Dr Chara Stavrou**, NIHR Academic Clinical Fellow & Specialist Registrar in Medical Oncology, Guy's & St Thomas NHS Trust, London
chara.stavraka@gstt.nhs.uk
- Dr Mari Thomas**, Consultant Haematologist UCLH, NIHR Cardiometabolic Programme, UCLH/UCL Cardiovascular BRC, London
mari.thomas@nhs.net
- Charlotte Tomlinson**, Consultant Genetic Counsellor, Clinical Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London
Charlotte.tomlinson@gstt.nhs.uk
- Dr Vishakha Tripathi**, Consultant Genetic Counsellor, Clinical Genetics, Guy's & St Thomas' NHS Foundation Trust, London
Vishakha.Tripathi@gstt.nhs.uk
- Miss Lisa Webber**, Consultant Gynaecologist and Subspecialist in Reproductive Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London
lisawebberteoh@googlemail.com

Dr Christopher Williams, Clinical Research Fellow and Medical Oncology Registrar, Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
c.williams1@leeds.ac.uk

Mr Nick Wood, Consultant Gynaecological Oncologist, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust
Nick.Wood@lthtr.nhs.uk

Editors

Dr Caroline Archer, Consultant Medical Oncologist, Portsmouth Oncology Centre, Portsmouth Hospitals University NHS Trust, Portsmouth
caroline.archer@porthosp.nhs.uk

Dr Ruth E Board, Consultant in Medical Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston
Ruth.Board@LTHTR.nhs.uk

Dr Melanie C Davies, Consultant Gynaecologist, Reproductive Medicine Unit, University College London Hospitals, London
melanie.davies14@nhs.net

Dr Eleni Karapanagiotou, Consultant Medical Oncologist, Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London
Eleni.Karapanagiotou@gstt.nhs.uk

Dr Julia Kopeika, Consultant Gynaecologist and Subspecialist in Reproductive Medicine and Surgery, Assisted Conception Unit, Guy's and St Thomas' NHS Foundation Trust, London
Yuliya.Kopeika@gstt.nhs.uk

Dr Janine Mansi, Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London
Janine.Mansi@gstt.nhs.uk

Preface

The progress made in cancer diagnosis and treatment has radically improved patient outcomes. More than 50% of people diagnosed with cancer can expect to achieve long-term survival in countries with well-developed healthcare systems. That steady and continuing improvement brings with it the requirement that we focus on the quality of life of cancer survivors. Cancer professionals and patients need to plan carefully together to manage any long-term consequences of cancer and its treatment that they may encounter. Such “Survivorship Care Plans” are widely recommended but not yet comprehensively taken up in all healthcare systems.

Increasing cancer survival rates and the trend towards a later parental age for childbirth mean that there is an increasing chance of a person being diagnosed with cancer before their family is complete. There are increasing numbers of patients for whom fertility following their cancer and its treatment has to be considered carefully; this is a central issue for these patients and professionals. The Association of Cancer Physicians (ACP) has worked with specialists in fertility on *Problem Solving in Cancer and Fertility*, bringing together the extensive and ever-increasing body of information about the way that cancer and its treatment can affect fertility, the way that fertility can be protected in many patients, and the important aspects of communication and a patient-centred approach which must underpin the provision of cancer care in this most important and sensitive area. The book will discuss exciting technological developments in the preservation and promotion of fertility in cancer patients, which has become a fast-moving field of research and innovation.

Patient concerns about their future fertility are well documented. For example, studies show that over 50% of women diagnosed with breast cancer and ovarian cancer express substantial concerns about impacts on fertility; young men diagnosed with cancer place the retention of fertility as a high priority. However, good quality discussions about fertility do not always occur between cancer patients and healthcare providers. Under some circumstances the cancer care team may prioritise the treatment on curing a cancer; some cancer professionals may lack knowledge of modern fertility preservation. There will be concerns about any risks of delay in treatment, or about increasing emotional distress if fertility is discussed in detail. However, these fertility discussions are central to high-quality survivorship for cancer patients in future. The best cancer care is delivered through a multidisciplinary team; all team members need to be aware of fertility issues for their patients, and some team members should take specific responsibilities to constantly review and audit team practice in this challenging area. The wider multidisciplinary team should involve specialists in fertility, and there need to be clear protocols to involve fertility specialists appropriately when this is needed.

This text on cancer and fertility includes a wide spectrum of issues which are illustrated as chapters and case histories. The perspective chapters cover fertility issues in women and men, including fertility preservation at the time of diagnosis; management, including drugs used during pregnancy; and survivorship issues such as conceiving after treatment, premature ovarian insufficiency, and surrogacy. There are also chapters on issues related to counselling, genetics and ethics. The case histories follow the same pathway as the chapters, but using sometimes complex histories to illustrate the principles and dilemmas.

The case histories are complementary to the chapters, and there are themes linking clinical scenarios as follows:

Female fertility and fertility preservation:

Chapters 1, 2 and Case histories 1, 2, 4, 5, 6, 21, 22

Male fertility and fertility preservation:

Chapters 3, 7 and Case histories 3, 7, 23

Cancer in pregnancy:

Chapters 4, 5 and Case histories 4, 8, 9, 10, 11,

Pregnancy after cancer in women and men:

Chapters 6, 9 and Case histories 4, 9, 12, 13, 14, 15, 18, 20, 21, 22, 23

Genetic issues:

Chapter 11 and Case histories 5, 19, 22

Premature ovarian insufficiency:

Chapters 8, 10 and Case histories 14, 15, 16, 17

Counselling and ethical issues:

Chapters 9, 12, 13 and throughout many of the case histories

LGBTQ:

Case histories 22, 23

The decision by the Association of Cancer Physicians to focus a workshop and Problem Solving publication on the fertility of cancer patients is a reflection of the progress and success in cancer treatment which we all welcome. However, it also illustrates very well the challenges which we have to face to ensure the best quality of cancer survivorship and the long-term wellbeing of cancer patients.

Peter Selby, President, Association of Cancer Physicians

*Eleni Karapanagiotou, Julia Kopeika, Ruth Board, Caroline Archer,
Melanie Davies, Janine Mansi, Editors*

David Cunningham, Chair, Association of Cancer Physicians

Acknowledgements

The editors and authors are grateful to all the patients who have inspired us to prepare this book and work together to improve their care.

The editors and authors are very grateful to Cancer Research UK (CRUK) for providing the funding to support this book. The editors, authors and publisher are most grateful to the Association of Cancer Physicians Executive for their support and advice during the development of this book.

We are very grateful to Duncan Enright at EBN Health for his expert work, support, goodwill and interest in our purpose in preparing the book, and Nicole Goldman, who coordinated and oversaw the book's preparation and organization.

Dr Karapanagiotou, Dr Kopeika and Dr Mansi would like to acknowledge the support of Guy's and St Thomas' NHS Foundation Trust. Dr Board would like to acknowledge the support of the University of Manchester and Lancashire Teaching Hospitals NHS Trust. Dr Archer would like to acknowledge the support of Portsmouth Hospitals University NHS Trust. Dr Davies would like to acknowledge the support of University College Hospital NHS Foundation Trust.

*Eleni Karapanagiotou, Julia Kopeika, Ruth Board, Caroline Archer,
Melanie Davies, Janine Mansi, Editors*

Association of Cancer Physicians

The 'Problem Solving' series of cancer-related books is developed and prepared by the Association of Cancer Physicians (ACP), often in partnership with one or more other specialist medical organizations. In this particular book, our co-editors are representatives from the Royal College of Obstetricians and Gynaecologists, and have a specialist interest in fertility.

As the representative body for medical oncologists in the UK, the ACP has a broad set of aims, including education for our own members and for non-members, including interested clinicians, healthcare professionals and the public. The Problem Solving Series is a planned sequence of publications that derive from a programme of annual scientific workshops initiated in 2014 with 'Problem Solving in Acute Oncology' followed by 'Problem Solving in Older Cancer Patients', 'Problem Solving through Precision Oncology', 'Problem Solving in Patient-Centred and Integrated Cancer Care', 'Problem Solving in Immunotherapy' and 'Problem Solving in Acute Oncology 2nd Edition'. 'Problem Solving in Cancer and Fertility' is the latest in the series.

The publication involves considerable work from members and other contributors and this work is done without remuneration, as an educational service. We have been delighted with the standard of the publications which have been well received. The BMA prize for Best Oncology Book of the Year was awarded to 'Problem Solving in Older Cancer Patients' in 2016, 'Problem

Solving in Precision Oncology' in 2017 and 'Problem Solving in Patient-Centred and Integrated Cancer Care' in 2018.

The ACP wishes to thank all the contributors to this book and our previous publications, and those which are yet to come.

David Cunningham, Chairman, Association of Cancer Physicians

Peter Selby, President, Association of Cancer Physicians

01 The Effects of Cancer and its Treatment on Female Fertility

Richard A. Anderson

Introduction

The treatment of cancer in young women is increasingly turning from focusing purely on survival to recognition of the long-term effects of treatment on subsequent quality of life. In this regard, fertility is a very high priority for patients. That cytotoxic therapies have adverse effects on fertility has been recognized since the very earliest days of the administration of mustard gas derivatives, and specifically in relation to the ovary, with demonstration of the effects of chemotherapeutic agents on growing follicles, resulting in amenorrhoea, and in the longer term resulting in loss of fertility and premature menopause. Pregnancy after cancer is also associated with increased risk, notably of prematurity and low birth weight.¹ The recognition of the importance of late effects on fertility have been paralleled by a substantial growth in the development and provision of fertility preservation services in reproductive medicine centres and the development of the necessary close links with oncology and other services, although this remains an area where much work needs to be done in improving awareness and access to services in the UK. Fertility preservation is a complex area, requiring a balance between accurate identification of those at risk and the provision of a sufficiently encompassing service, with issues including equality of access, informed decision making regarding the experimental nature of some procedures and provision of funding. From the patient's perspective, this is all undertaken at very short notice at a time of enormous stress following a recent diagnosis when many other tests and investigations also need to be undertaken. Subsequent fertility is also part of a broader survivorship agenda, recognizing that most cancer survivors have significant health issues which may impact directly or indirectly on their fertility, for example the recognition that survivors of brain and CNS cancers have reduced chance of marriage or co-habitation. There may additionally be concerns about starting or completing a family following such a serious diagnosis, as well as concerns, now recognized to be unsubstantiated, that a pregnancy following, for example breast cancer may increase the risk of recurrence.

Recent developments

The effects of chemotherapeutic agents on the ovary will almost invariably involve loss of the growing population of follicles, related to their rapid cell proliferation and sensitivity to cytotoxic agents. This is likely to result in a rapid decline in oestrogen levels, and often amenorrhoea. However it is the risk to the non-growing primordial follicle pool that is most important in determining the long-term effects, and potential recovery of the ovary,² as they constitute the 'ovarian reserve'. Primordial follicles are formed in fetal life and thereafter a small proportion start to grow every day; subsequently the growing follicles develop fluid-filled cavities (antra) and increasingly produce oestrogen, culminating in ovulation. The number of primordial follicles is therefore progressively depleted over time, with near-exhaustion resulting in the menopause.

Premature loss of primordial follicles, as occurs with some chemotherapies, will therefore bring forward the time of the menopause, ultimately during or shortly after treatment. Remaining primordial follicles will start to grow, thus ‘repopulating’ the growing follicle populations of the ovary, with restoration of menses and fertility. This may however be short-lived. Additionally, while the follicle pool is the most important target within the ovary, effects on the vasculature and ovarian stroma are also very relevant and may significantly comprise later follicle growth: these may be affected by chemotherapy as well as radiotherapy. These effects of treatment are depicted in Figure 1.1.

As the primordial follicle pool can only be determined histologically, many studies rely on surrogate biochemical or clinical outcomes. These include anti-müllerian hormone (AMH), which is produced by the smaller antral follicles (Figure 1.1), ultrasound measures of the antral follicle count and most commonly the presence or absence of menses, commonly recorded as chemotherapy related amenorrhoea. AMH has become the most useful biomarker of the ovarian reserve in this and other clinical situations, particularly as it does not vary to an important degree across the menstrual cycle. It does however vary in other important clinical situations, most notably being reduced by perhaps as much as 30% in women taking the combined contraceptive pill, and may also be reduced in women with cancer at the time of diagnosis. The more important clinical outcomes are much more difficult to determine and include fertility and age at menopause, with other patient-critical outcomes such as time to pregnancy and attaining desired family size, rarely if ever described. The endocrine-related functions of the ovary, for example in supporting bone mass and quality of life through recording of issues such as hot flushes and joint pains, are also sometimes investigated and are important aspects of the non-reproductive aspects of ovarian function.




Figure 1.1 Representation of the effects of gonadotoxic treatment on the ovary. The number of primordial and early growing follicles in a healthy ovary is reduced by some chemotherapy regimens, with additional effects on the ovarian vasculature and stroma. If a sufficient population of primordial and thus early growing follicles remains, development of pre-ovulatory follicles will continue allowing the potential for post-treatment fertility. Otherwise, complete depletion results in premature ovarian insufficiency (POI), infertility and oestrogen deficiency. Ongoing post-treatment ovarian function may develop into POI, depending on the remaining ovarian reserve.²

In addition to the ovary, the uterus is also a key target of damage through radiotherapy to the pelvis, particular before puberty. Radiotherapy damage to the uterus may result in early or late miscarriage, premature delivery, stillbirth and post-partum haemorrhage.³ The central control pathways of the hypothalamus and pituitary may also be damaged by surgery or cranial radiotherapy, with sometimes subtle but progressive effects on ovulatory control reported.

Due to the progressive decline in the number of follicles within the ovary with age, and the variability from one woman to the next, treatment effects are superimposed on a very wide-ranging background level of ovarian function. The effect of age is well-described, with data showing an increased prevalence of infertility with increasing age at diagnosis even in women with ongoing ovarian function, as well as changes in the prevalence of post-treatment amenorrhea. There are limited data on risk of early menopause, but for example in the case of Hodgkin's lymphoma, the varying risk with different therapies has been clearly described with minimal risk of early menopause following ABVD therapy, but with substantial and increasing risk with alkylating based therapy, pelvic radiotherapy and particularly the combination.⁴ Data relating to fertility after cancer therapy are more scarce, and better provided in the paediatric than adult setting. The United States Childhood Cancer Survivors Study has provided considerable data for many years now, and recent data on women treated with chemotherapy only show the importance of specific therapies but against an overall positive finding of a hazard ratio for live birth of 0.87 (95% CI 0.81–0.92).⁵ That analysis does however highlight the effect of later age at conception, with a widening of the difference between cancer survivors and their siblings in women who had not conceived before the age of 30. To broaden these data and provide an unbiased risk, we undertook an analysis of population based databases in Scotland recording all diagnoses of cancer up to the age of 40 against subsequent pregnancies, with outcomes compared to the general population standardized for age at diagnosis, interval since and deprivation.⁶ Overall, this showed that women were 38% less likely to achieve a pregnancy after a cancer diagnosis than women in the general population and this was across all diagnostic groups (Figure 1.2). Cervical and breast cancer made the




Figure 1.2 Standardized incidence rate (SIR, with 95% CI) for pregnancy after cancer by diagnosis. Data are for female patients ($n = 23,201$) diagnosed below the age of 40 years between 1981 and 2012 in Scotland, with subsequent pregnancies or death up until the end of 2014, compared to population controls. Standardized for age, deprivation and year of diagnosis. Data from Ref. (6).




Figure 1.3 Adjusted hazard ratio (HR, with 95% CI) for first pregnancy after cancer diagnosis by period of diagnosis for women with breast, Hodgkin's lymphoma, cervical, leukaemia and brain/CNS cancers. Reprinted with permission from Ref. (6).

greatest impact with standardized incidence ratios of 0.34 and 0.39, respectively, but in both cases there have been substantial improvements in the likelihood of achieving a pregnancy across the period of analysis from 1981 to 2012, particularly for cervical cancer (Figure 1.3). This may be an effect of the introduction of cervical screening and thus earlier, less aggressive surgical treatment for cervical cancer, and changes in chemotherapy regimens for breast cancer. For other diagnoses, notably leukaemia and brain/CNS cancers, there has not been any apparent improvement in the chance of pregnancy after diagnosis over these years. Perhaps indicating greater health-awareness after cancer, this analysis also showed that the likelihood of a pregnancy resulting in termination was, in fact, significantly reduced following a cancer diagnosis, particularly in those diagnosed in childhood and adolescence. There were additional improvements in the mode of delivery, with a normalization of the rate of elective caesarean section.¹

There has been much interest in the value of the measurement of AMH as an index of cancer treatment induced damage to the ovary, first demonstrated in survivors of childhood cancer despite their continuing to have regular menstrual cycles.⁷ This finding has been replicated in many other studies and it has also been shown that pre-treatment AMH will predict long-term ovarian function, particularly in the context of breast cancer treatment.⁸ In that study, all women with pre-treatment AMH <1.9 ng/ml (13.5 pmol/l) showed long-term amenorrhoea, and a value of 0.71 ng/ml (5.0 pmol/l) had peak likelihood ratio of 7 for predicting ongoing menses, with sensitivity 54% and specificity 92%. AMH very clearly distinguishes between high and low risk gonadotoxicity treatments, for example comparing ABVD treatment with BEACOPP: there is complete recovery of AMH levels in women treated with ABVD but only very low post-treatment levels following BEACOPP.⁹ Intriguingly, however, even following ABVD there was evidence of an impact of age on the rate and extent of recovery, with compromised recovery in women over the age of 35.

While other articles in this series will discuss approaches to fertility preservation, it is now clear from several large randomized control trials that GnRH agonist treatment during chemotherapy for breast cancer does reduce the prevalence of premature ovarian insufficiency thereafter.¹⁰ Meta-analysis indicates an odds ratio of 0.37, with a very similar result from an individual patient data analysis approach, with an odds ratio of 0.38. However, it is important to recognize that these studies only followed-up women for relatively short periods of time, generally no longer than 2 years, and therefore the true benefits of this apparent protective effect on either fertility or the non-reproductive endocrine aspects of ovarian function have not been clearly determined. Notably, the OPTION trial was the only large randomized controlled trial to include AMH measurement to assess ovarian reserve post-treatment, and this showed no difference in AMH levels following recovery between those who did or did not have GnRH agonist treatments during chemotherapy.¹¹ A wide range of other pharmacological approaches to protect the ovary are also being investigated, but these remain in the pre-clinical stage.

Conclusion



Fertility preservation is now a part of mainstream medicine, which recognizes the importance of fertility after cancer treatment to many women. There is an ongoing need for improved accuracy of patient-specific assessment of risk to their fertility and ovarian function, focusing on their proposed treatment, but also in the context of intrinsic issues, notably their age and ovarian reserve. It is to be hoped that in the future, this will allow more tailored and effective use of fertility preservation techniques, with long-term outcome studies also addressing the non-reproductive health benefits of improved ovarian function.

References



- 1 van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, *et al.* Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. *Eur J Cancer* 2019; 111: 126–37.
- 2 Jayasinghe YL, Wallace WHB, Anderson RA. Ovarian function, fertility and reproductive lifespan in cancer patients. *Expert Rev Endocrinol Metab* 2018; 13(3): 125–36.
- 3 Signorello LB, Mulvihill JJ, Green DM, *et al.* Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. *Lancet* 2010; 376(9741): 624–30.
- 4 Swerdlow AJ, Cooke R, Bates A, *et al.* Risk of premature menopause after treatment for Hodgkin's lymphoma. *J Natl Cancer Inst* 2014; 106(9): dju207.
- 5 Chow EJ, Stratton KL, Leisenring WM, *et al.* Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. *Lancet Oncol* 2016; 17(5): 567–76.
- 6 Anderson RA, Brewster DH, Wood R, *et al.* The impact of cancer on subsequent chance of pregnancy: a population-based analysis. *Hum Reprod* 2018; 33(7): 1281–90.
- 7 Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. *Hum Reprod* 2003; 18(11): 2368–74.

- 8 Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. *J Clin Endocrinol Metab* 2011; 96(5): 1336–43.
- 9 Anderson RA, Remedios R, Kirkwood AA, *et al.* Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. *Lancet Oncol* 2018; 19(10): 1328–37.
- 10 Lambertini M, Moore HCF, Leonard RCF, *et al.* Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. *J Clin Oncol* 2018; 36(19): 1981–90.
- 11 Leonard R, Adamson D, Bertelli G, *et al.* GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. *Ann Oncol* 2017; 28(8): 1811–6.

Index

Note: page numbers in *italics* refer to figures and tables.

- 5-fluorouracil, effect on testicular function 155
- ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) 92, 137
- fertility risk 93
 - ovarian toxicity 4–5
- acute lymphoblastic leukaemia (ALL) 126–30, 132–5
- adolescent boys, sperm cryopreservation 102
- afatinib
- use during pregnancy 121
 - see also* tyrosine kinase inhibitors
- age, effect on female fertility 3
- anastrozole 141
- alternative treatments 143–4
 - see also* aromatase inhibitors
- androgen receptor positivity, breast cancer 172–3
- anthracyclines
- cardiotoxicity 124, 134
 - subsequent pregnancy 124, 134
 - use during pregnancy 25, 26
- anticoagulation
- case study 137–40
 - during pregnancy 27, 139
- anti-emetics, use during pregnancy 26, 27
- anti-müllerian hormone (AMH) 38
- as marker of ovarian damage 2, 4–5
 - in pregnancy and post-partum period 83
- apixaban 137
- aromatase inhibitors 146
- anastrozole 141
 - alternative treatments 143–4
 - effect on bone health 147
 - SOFT and TEXT studies 144, 147
- artificial ovaries 46, 170
- Asherman's syndrome (AS) 164
- assisted reproduction 31
- in azoospermia, case studies 152–5
 - pre-implantation genetic diagnosis 57–8
 - in premature ovarian failure 40–1
 - use of banked sperm 36
 - see also* egg donation; *in-vitro* fertilization; sperm donation
- ATLAS trial 125
- atrophic vaginitis 142
- aTTom trial 125
- autonomy 65–6
- azoospermia 100
- assisted reproduction, case study 152–5
 - fertility options 80, 153
 - post-treatment 101
- BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) 92
- fertility risk 93
 - ovarian toxicity 4
- BEAM (carmustine, etoposide, cytarabine, melphalan) 137
- beneficence 66
- BEP (bleomycin, etoposide, cisplatin) 177
- effects on male fertility 79, 178
- bereavement support 62
- bio-identical HRT 39
- birth defects, incidence 24
- bisphosphonates 53, 146, 149
- adverse effects 149
 - use during pregnancy 27
- bone health
- case study 146–50
 - investigations 148
 - osteoporosis/osteopenia management 148–9
 - risk factors for osteoporosis 147–8
- Bone Marrow Transplant Survivor Study (BMTSS) 127, 133
- bone marrow transplantation
- effect on female fertility 127
 - effect on male fertility 127–8
 - long-term health effects 128
 - pregnancy 126–30, 129
 - pre-pregnancy review 128–9
- BRAF* mutation 88
- brain/CNS cancer
- female fertility preservation 9
 - pregnancy rates after therapy 3, 4
- BRCA1* mutation 55, 56
- ovarian cancer risk 159
- BRCA2* mutation
- breast cancer in a transgender man 172–5
 - inheritance 159–60
 - ovarian cancer risk 159
 - prophylactic surgery 157–60

- breast cancer 30
 - androgen receptor positivity 172–3
 - case studies
 - bone health 146–50
 - BRCA2 mutation 157–60
 - fertility preservation 69–71
 - premature ovarian insufficiency 141–4
 - in a transgender man 172–5
 - unexpected pregnancy 111–14
 - ER positive
 - POI management 52–3
 - safety of HRT 143
 - safety of ovarian stimulation 70–1
 - safety of vaginal oestrogens 52, 143
 - fertility preservation 9, 69–71
 - hereditary syndromes 56, 57
 - metastatic, CLEOPATRA trial 112
 - ovarian suppression 158
 - in pregnancy 111–14
 - diagnosis in pregnancy 20
 - incidence in pregnancy 19
 - treatment 26, 112–13
 - registries 28
- breast cancer survivors
 - assisted reproduction 31
 - breast feeding 31
 - contraception 31–2
 - pregnancy
 - case study 123–5
 - rates 30
 - safety issues 30–1
 - success rates 3, 4
 - timing of 31
- breast feeding 23, 27
 - breast cancer survivors 31, 124
- busulphan, effect on female fertility 127
- calcium intake 40, 53
- cancer in pregnancy
 - breast cancer 111–14
 - delivery
 - early 23
 - timing of 22
 - diagnosis 20–1
 - incidence 19–20
 - management 21–2, 27
 - surgery 21
 - systemic anti-cancer treatment 25–7, 26, 28
 - potential risks 24–5
- cancer survivors
 - assisted reproduction 31
 - contraception 31–2
 - male fertility
 - assisted reproduction 36
 - natural paternity 35–6
 - spermatogenesis 35
 - pregnancy
 - neonatal outcomes 31
 - rates 30
 - safety issues 30–1
 - timing of 31
 - see also* breast cancer survivors
 - capecitabine, effect on testicular function 155
 - carboplatin, effect on male fertility 35
 - cardiotoxicity 124, 128, 134
 - cardiovascular disease risk 39
 - after bone marrow transplantation 128
 - after oophorectomy 158
 - case studies
 - breast cancer in a transgender man 172–5
 - female fertility preservation
 - cervical cancer 73–6
 - early breast cancer 69–71
 - ovarian tissue cryopreservation 92–7, 167–70
 - post-partum 82–5
 - Lynch syndrome 87–90
 - male fertility preservation
 - inability to produce sperm sample 96
 - testicular cancer 78–81
 - pregnancy
 - after bone marrow transplant 126–30
 - after breast cancer treatment 123–5
 - after micro-TESE 152–5
 - after paternal pembrolizumab therapy 105–9
 - after radical trachelectomy 162–5
 - cancer diagnosis 119–22
 - in Hodgkin lymphoma 115–18
 - in metastatic breast cancer 111–14
 - premature ovarian insufficiency 132–5
 - bone health 146–50
 - HRT and VTE 137–40
 - vaginal symptoms and hot flushes 141–4
 - salpingo-oophorectomy in BRCA positive breast cancer 157–60
 - testicular cancer in a gay man 177–80
 - cervical cancer
 - fertility counselling 75–6
 - fertility preservation 9
 - case study 73–6
 - incidence in pregnancy 19
 - pregnancy management 75
 - pregnancy rates after therapy 3, 4

- treatment options 74
- cervical cerclage 75, 126, 165
 - indications for 129
- cervical screening, transgender men 175
- cervical stenosis 162, 163–4
- checkpoint inhibitors (CPIs)
 - adverse effects 106
 - fertility implications 107–8
 - pregnancy after paternal use 105–9
 - pregnancy avoidance recommendations 107
 - pregnancy outcomes 106–7
 - use during pregnancy 117
- chemotherapy
 - advice on sexual intercourse 179
 - effects on male fertility 79
 - effects on testicular function 154–5
 - impact on intrauterine growth restriction 22
 - pregnancy avoidance 179
 - see also* specific agents and regimens
- chlorambucil, effect on testicular function 155
- chorioamnionitis 163
- chronic myeloid leukaemia 117
 - systemic therapy during pregnancy 26–7
- CLEOPATRA trial 112
- clomiphene 164
- colorectal cancer
 - female fertility preservation 9
 - hereditary syndromes 57
 - pregnancy rates after therapy 3
 - see also* Lynch syndrome
- combined hormonal contraception (CHC) 39
- conjugated equine oestrogens 50
- contraception 31–2
 - after cervical cancer 75–6
 - combined hormonal 39
 - during SACT 116
- controlled ovarian stimulation (COS) 7–8, 167, 169
 - in myelodysplastic syndromes 84–5
 - in post-partum period 83–4
 - safety in ER positive breast cancer 70–1
 - VTE risk 138
- counselling
 - after trachelectomy 75
 - fertility 60–1
 - after cervical cancer 75–6
 - gamete donation 62–3
 - welfare of child assessment 61–2
 - genetic 55, 58
 - in *BRCA2* mutation 159–60
 - in unexpected pregnancy 112, 117
- Cowden syndrome 57
- cranial irradiation, long-term effects 128
- crizotinib
 - use during pregnancy 26
 - see also* tyrosine kinase inhibitors
- CT scans 120
- cyclophosphamide
 - effect on female fertility 127
 - effect on testicular function 155
 - use during pregnancy 26
- cytotoxic therapy
 - effects on the ovary 1–2, 4–5
 - use during pregnancy 25–6, 121
 - see also* chemotherapy
- deep venous thrombosis *see* venous thromboembolism
- dehydroepiandrosterone (DHEA), vaginal 52–3
- denosumab 149
- DEXA (dual energy X-ray absorptiometry) 148
- DHAP (dexamethasone, high-dose cytarabine, cisplatin) 93
- directly-acting oral anticoagulants (DOACs) 139
- docetaxel 112
- doxorubicin
 - effect on testicular function 155
 - subsequent pregnancy 124
 - see also* anthracyclines
- egg donation 40, 43, 134
 - case study 132–5
 - donor recipient cycles 44
 - donor screening and exclusion criteria 43
 - donor treatment 44
 - ethical issues 67
 - legal aspects 46, 62–3
 - obstetric risks 135
 - pre-treatment preparation 43
 - recipient treatment 44–5
 - source of eggs 45
 - success rates 45
- egg retrieval, synchronization with micro-TESE 153–4
- egg/embryo cryopreservation 94–5
 - avoidance after recent chemotherapy 93–4
 - case study 69
 - controlled ovarian stimulation 7–8
 - ethical issues 65–7, 66–7
 - freezing methods 8
 - oocytes vs. embryos 8–9, 71
 - time required 70

- electroejaculation (EEJ) 101, 102
- endocrine cancer, hereditary syndromes 57
- endometrial cancer
 - Lynch syndrome 88, 89–90
 - risk from tamoxifen 159
 - survivors, assisted reproduction 31
- epirubicin
 - subsequent pregnancy 124
 - use during pregnancy 112–13
 - see also* anthracyclines
- erlotinib
 - use during pregnancy 26, 121
 - see also* tyrosine kinase inhibitors
- escitalopram 142
- ethical issues
 - duration of cryopreservation 66–7
 - gamete donation 62–3
 - general principles 65–6
 - pre-implantation genetic diagnosis 58
 - prenatal diagnosis 58
 - termination of pregnancy 117–18
 - third party assisted reproduction 67
 - welfare of child assessment 61–2
- ethinyl oestradiol 50–1
- etoposide, effect on testicular function 155
- exemestane
 - SOFT and TEXT studies 144, 147
 - see also* aromatase inhibitors
- factor V Leiden 138
- familial adenomatous polyposis 57
- familial retinoblastoma 57
- female fertility 1
 - age-related effects 3
 - cytotoxic effects on the ovaries 1–2
 - effect of childhood bone marrow transplantation 127
 - pregnancy rates after cancer therapy 3–4
 - radiotherapy damage to the uterus 3
- female fertility preservation 5, 46, 159
 - case studies
 - breast cancer 69–71
 - cervical cancer 73–6
 - Lynch syndrome 87–90
 - ovarian tissue cryopreservation 92–7
 - post-partum 82–5
 - diminishing off-target effects 10
 - egg/embryo cryopreservation
 - controlled ovarian stimulation 7–8
 - ethical issues 65–7
 - oocytes vs. embryos 8–9, 71
 - preservation methods 8
 - risks 8, 9, 70–1
 - time required 70
 - funding 10
 - GnRH agonists 10
 - in myelodysplastic syndromes 84–5
 - options 7
 - ovarian tissue cryopreservation 9–10, 70, 95
 - advantages and limitations 169
 - after first-line chemotherapy 96
 - case studies 92–7, 167–70
 - endocrine function restoration 168
 - procedure 168
 - recent advances 170
 - risks 169
 - subsequent pregnancy 168–9
- female infertility management 40–1
 - egg donation 43–6
 - case study 132–5
 - future concepts 46, 47–8
 - surrogacy 46–8
- fertility *see* female fertility; male fertility
- fertility counselling 60–1
 - after cervical cancer 75–6
 - gamete donation 62–3
 - welfare of child assessment 61–2
- Fertility Network UK 63, 64
- fertility preservation
 - ethical issues
 - duration of cryopreservation 66–7
 - general principles 65–6
 - posthumous use 67
 - hereditary cancer syndromes 56–7
 - see also* female fertility preservation; male fertility preservation
- fetal metastases 27
- fluoropyrimidines 89
- follicle-stimulating hormone (FSH)
 - controlled ovarian stimulation 7, 8
 - in egg donation 44
- FSH Window 7
- funding 66, 67, 178
- gadolinium 83
- gamete donation
 - donor contact 63
 - implications of 62–3
 - see also* egg donation; sperm donation
- gamete preservation methods 8

- gefitinib
 use during pregnancy 26, 121
see also tyrosine kinase inhibitors
- genetic counselling 55
 in *BRCA2* mutation 159–60
 pre-implantation genetic diagnosis 58
- genetic testing 55
- GnRH agonists 142
 in COS 84
 in egg donation 44
 female fertility preservation 5, 10
- GnRH antagonists
 in COS 84
 in egg donation 44
- goserelin 141, 142
 alternative treatments 143–4
- graft-versus-host disease (GvHD) 128
- granulocyte stimulating factors, use during pregnancy 26, 27
- growth factors, use during pregnancy 26, 27
- HABITS trial 143
- haematological cancers
 incidence in pregnancy 19
see also Hodgkin's lymphoma; leukaemias; lymphoma
- haematometra 162, 164
- heparin, use during pregnancy 139
- HER2 targeted therapy 112
 effects on pregnancy 113
 use during pregnancy 26
 unexpected pregnancy 111–14
- hereditary cancer syndromes (HCS) 55, 57
 fertility preservation 56–7
 pregnancy 59
 pre-implantation genetic diagnosis 57–8
 prenatal diagnosis 58
 reproductive options 58
- hereditary non-polyposis colorectal cancer (HNPCC) 57, 88
see also Lynch syndrome
- hereditary phaeochromocytoma/paranglioma syndrome 57
- Hodgkin's lymphoma
 case studies 92–7, 137
 unexpected pregnancy 115–18
 female fertility preservation, options 94–5
 male fertility 35
 pregnancy rates after therapy 3, 4
 risk of early menopause 3
- hormone replacement therapy (HRT) 39–40, 50
 association with venous thromboembolism 138–9
 case studies 137–40, 141–4
 oestrogen 50–1
 progestogens 51–2
 risks and benefits 138
 safety after ER+ve breast cancer 143
 testosterone, role in women 52
- hot flushes
 case study 141–4
 management options 142–3
 non-hormonal treatments 53
- Human Fertilisation and Embryology Authority (HFEA)
 code of practice
 gamete donation 43, 46, 62
 welfare of child assessment 61
 donor information provision 63
- Human Fertilisation and Embryology Authority Act, 2008 47
- hypercoagulability 138
- hypertensive disorders of pregnancy, risk after oocyte donation 135
- hypophysitis 106
- hypothyroidism, effect on pregnancy outcome 129, 130
- ICE (ifosfamide, carboplatin, etoposide) 93
- imaging during pregnancy 20–1, 83, 113, 120
 fetal radiation exposure 20
- imatinib
 gonadoprotection 46
 use during pregnancy 26–7, 117
see also tyrosine kinase inhibitors
- immunotherapy
 effects on testicular function 154–5
see also checkpoint inhibitors; monoclonal antibodies
- in-vitro* fertilization (IVF)
 after radical trachelectomy 162
 pre-implantation genetic diagnosis 57–8
 using banked sperm 36
 using donor eggs 40, 43
see also assisted reproduction
- in vitro* oocyte maturation 95, 170
- intracytoplasmic sperm injection (ICSI) 100
- intrauterine adhesions 164
- intrauterine growth restriction (IUGR) 22
- intrauterine systems (IUS) 39

- ipilimumab
 - pregnancy avoidance recommendations 107
 - see also* checkpoint inhibitors
- jaw, medically-related osteonecrosis 149
- justice 66
- legal issues
 - gamete donation 62–3
 - surrogacy 47, 179
- letrozole 146
 - see also* aromatase inhibitors
- letrozole–FSH protocol 70–1
- leukaemias, pregnancy rates after therapy 3, 4
- Li-Fraumeni syndrome 57
- low-molecular weight heparins (LMWH), use
 - during pregnancy 139
- lung cancer
 - diagnosis during pregnancy 119–22
 - systemic therapy during pregnancy 26
- lymphoma
 - case study 167–70
 - female fertility preservation 9
 - see also* Hodgkin's lymphoma
- Lynch syndrome 57
 - case study 87–90
 - female fertility issues 89
 - genetic abnormalities 88
 - genetic testing 88
 - pre-implantation genetic testing 89
 - surveillance 89–90
- Macmillan Cancer Support 63, 64
- magnetic resonance imaging (MRI) 20, 83, 113, 120
- male fertility
 - cancer survivors
 - assisted reproduction 36
 - natural paternity 35–6
 - spermatogenesis 35
 - effect of childhood bone marrow
 - transplantation 127–8
 - effect of BEP 178
- male fertility preservation 12–13, 16, 34–5
 - case studies 78–81, 177–80
 - inability to produce sperm sample 96
 - options 13
 - service requirements 13
 - in testicular cancer 13–15, 78–81, 177–80
 - use of banked sperm 36
- medically-related osteonecrosis of the jaw
 - (MRONJ) 149
- melanoma
 - incidence in pregnancy 19
 - metastatic, case study 105
- melphalan, effect on female fertility 127
- menopause, premature *see* premature ovarian insufficiency
- menstrual suppression, VTE risk 138
- mercaptopurine, effect on testicular function 155
- methotrexate, effect on testicular function 155
- metoclopramide, use during pregnancy 27
- micro TESE 13, 14, 101
 - case studies 80, 81, 152–5
 - in post-treatment azoospermia 101
 - retrieval rates 153
 - synchronization with egg retrieval 153–4
- microsatellite instability 88
- Million Women study 39
- miscarriage
 - after SACT, case study 115–18
 - incidence 24
- mismatch repair (MMR) protein defects 88
- MLH1* 88
- monoclonal antibodies
 - breast feeding 27
 - use during pregnancy 25
- MSH2* 88
- MSH6* 88
- multiple endocrine neoplasia (MEN) 57
- myelodysplastic disease, female fertility
 - preservation 9, 82–5
- neurofibromatosis type 1 57
- nivolumab
 - pregnancy avoidance recommendations 107
 - see also* checkpoint inhibitors
- non-Hodgkin's lymphoma (NHL)
 - case study 167–70
 - female fertility preservation 9
- non-maleficence 66
- norethisterone, menstrual suppression 138
- oestradiol preparations 50
- oestrogen replacement therapy 39–40
 - doses 51
 - oestrogen formulations 50–1
 - see also* hormone replacement therapy
- oestrogen-sensitive cancers
 - POI management 52–3
 - safety of HRT 143
 - safety of ovarian stimulation 70–1
 - safety of vaginal oestrogens 52, 143
- oncofertility services 13, 14–15, 16

- onco-microTESE 14, 80, 81
- ondansetron, use during pregnancy 27
- oocytes
 - production from stem cells 46
 - see also* egg donation; egg/embryo cryopreservation
- oophorectomy
 - case study 157–60
 - long-term health effects 158
- OPTION trial 5
- osteoblastic osteosarcoma 99–104
- osteoporosis/osteopenia 39, 53
 - case study 146–50
 - investigations 148
 - management 148–9
 - risk after oophorectomy 158
 - risk factors for 147–8
- ovarian cancer
 - fertility preservation 9
 - hereditary syndromes 56
 - incidence in pregnancy 19
 - Lynch syndrome 88, 89–90
 - pregnancy rates after therapy 3
 - risk in *BRCA* carriers 159
- ovarian hyperstimulation syndrome (OHSS) 8
- ovarian reserve 1–2
 - assessment 69, 70, 132, 133
 - post-partum period 83
 - biomarkers of 2
- ovarian stimulation *see* controlled ovarian stimulation
- ovarian suppression 158
- ovarian tissue cryopreservation 9–10, 70, 95
 - advantages and limitations 169
 - after first-line chemotherapy 96
 - case studies 92–7, 167–70
 - endocrine function restoration 168
 - procedure 168
 - recent advances 170
 - risks 169
 - subsequent pregnancy 168–9
- ovaries, effects of cytotoxic therapy 1–2
- ovulation suppression, post-partum period 83
- oxybutynin 143
- paraganglioma 57
- paroxetine 142
- partner status 177–8
- PD-1, PD-L1 expression, relationship to pregnancy
 - loss 107
- pembrolizumab
 - pregnancy after paternal use 105–9
 - see also* checkpoint inhibitors
- percutaneous epididymal sperm aspiration (PESA) 13, 101
- pertuzumab 112
 - effects on pregnancy 113
- Peutz–Jeghers syndrome 57
- phaeochromocytoma 57
- phytoestrogens 52
- placental metastases 27
- platinum-based therapy
 - effect on testicular function 155
 - effects on female fertility 89
 - effects on male fertility 79
 - use during pregnancy 25, 26, 121
- PMS2 88
- polycarbofil preparations 142
- polycystic ovary syndrome (PCOS) 162
- POSITIVE study 124
- posthumous use of cryopreserved material 67
- post-partum fertility preservation 82–5
- post-partum VTE risk 84
- pregnancy
 - anticoagulation 27, 139
 - cancer survivors 30, 75, 123–30, 162–5
 - neonatal outcomes 31
 - safety issues 30–1
 - timing 31
 - cardiotoxicity-related risks 134
 - case studies
 - after bone marrow transplant 126–30
 - after breast cancer treatment 123–5
 - after paternal pembrolizumab therapy 105–9
 - after radical trachelectomy 162–5
 - cancer diagnosis 119–22
 - in metastatic breast cancer 111–14
 - chemotherapy during 112–13
 - delivery
 - early 23
 - timing of 22, 121
 - diagnosis of cancer 20–1, 83, 119–22
 - discovery after cancer diagnosis 20
 - effects of anti-HER2 therapy 113
 - hereditary cancer syndromes 59
 - hypothyroidism 129, 130
 - imaging 20–1, 83, 120
 - incidence of cancer 19–20
 - intrauterine growth restriction, impact of
 - treatment 22
 - management 21–2, 27
 - in premature ovarian failure 41
 - radiation exposure, fetal doses 20
 - surgery 21

- pregnancy (*continued*)
- systemic anti-cancer treatment 25–7, 26, 28
 - potential risks 24–5
 - thromboprophylaxis 139
 - thrombosis risk 22, 27
 - after trachelectomy 75
 - unexpected
 - counselling 112, 117
 - management of 105, 112–14, 115–18
 - pregnancy status policies 116
 - pre-implantation genetic diagnosis (PGD) 57–8
 - Lynch syndrome 89
 - premature ovarian insufficiency (POI) 1–2, 2, 38
 - after oestrogen-sensitive cancers 52–3
 - case studies 132–5
 - bone health 146–50
 - HRT and VTE 137–40
 - vaginal symptoms and hot flushes 141–4
 - definition 38
 - diagnosis 38
 - fertility options 134
 - health consequences 39
 - health surveillance 41
 - hormone replacement therapy 39–40, 50
 - oestrogen 50–1
 - progestogens 51–2
 - testosterone 52
 - infertility management 40–1
 - egg donation 43–6
 - future concepts 46
 - investigations 142
 - lifestyle advice 40
 - risk assessment 70
 - risk in Hodgkin's lymphoma 3
 - spontaneous pregnancy 40, 133
 - survivorship issues 38
 - VTE risk 52
 - premature rupture of membranes (PROM) 163
 - prenatal diagnosis (PND) 58
 - primordial follicle pool 1–2
 - primordial follicles, *in vitro* growth 170
 - progestogen replacement therapy 51
 - doses 51–2
 - IUS 39
 - prophylactic surgery
 - BRCA positive breast cancer 157–60, 174
 - Lynch syndrome 90
 - prostate cancer 56
 - pulmonary embolism *see* venous thromboembolism
 - radical trachelectomy 74
 - cervical stenosis 163–4
 - fertility and obstetric outcomes 74–5, 163
 - subsequent pregnancy 75
 - case study 162–5
 - radiography *see* imaging during pregnancy
 - radiotherapy
 - childhood
 - effect on female fertility 127
 - effect on male fertility 127–8
 - obstetric risks 134
 - dose required to cause POI 133–4
 - effect on the uterus 3
 - fetal radiation exposure 22
 - testicular 79
 - R-AVD (rituximab, doxorubicin, vinblastine, dacarbazine), accidental pregnancy 115–18
 - refractory anaemia with excess blasts (RAEB) 82–5
 - retinoblastoma 57
 - salpingo-oophorectomy, risk-reducing 157–60, 174
 - same-sex couples
 - case study 177–80
 - fertility rights 178
 - selective oestrogen receptor modulators (SERMS)
 - endometrial effects 159
 - see also* tamoxifen
 - selective serotonin reuptake inhibitors (SSRIs) 142
 - seminoma 178
 - serotonin-noradrenaline reuptake inhibitors (SNRIs) 142–3
 - sexual intercourse, advice during
 - chemotherapy 179
 - sexual orientation 177–8
 - sildenafil 99, 100
 - skin cancer
 - pregnancy rates after therapy 3
 - see also* melanoma
 - slow-freezing gamete preservation 8
 - SOFT study 144, 147
 - sperm cryopreservation 13, 100
 - in adolescent boys 102
 - after micro-TESE 153–4
 - assisted reproduction 36
 - case studies 78–81
 - inability to produce sperm sample 96
 - counselling 178–9
 - ethical issues 65–7
 - indications for 34–5

- prior investigations 179
- referral for 34
- retrieval techniques 13, 14
 - electroejaculation 101
 - sildenafil 100
 - surgical options 101, 153
- in testicular cancer, optimal timing 79–80
- sperm donation 153
 - ethical issues 67
 - implications of 62–3
- spermatogenesis
 - effect of immune checkpoint inhibitors 107
 - effect of testicular cancer treatment 79
 - effects of chemotherapy and immunotherapy 154–5
 - recovery post-treatment 35
- spermatogonial stem cell (SSC) preservation 13
- stem cell transplantation (SCT), case study 132–5
- Stockholm trial 143
- surgery, prophylactic
 - BRCA positive breast cancer 157–60, 174
 - Lynch syndrome 90
- surgery during pregnancy 21
 - impact on intrauterine growth 22
- surrogacy 46
 - clinical aspects 46–7
 - ethical issues 67
 - financial aspects 47, 178–9
 - legal aspects 47, 179
 - screening 47
- systemic anti-cancer treatment (SACT)
 - breast feeding 27
 - effects on testicular function 154–5
 - during pregnancy 25–7, 28, 120–1
 - risks 24–5, 26
 - pregnancy avoidance 116
 - pregnancy status policies 116
 - see also* checkpoint inhibitors; chemotherapy; cytotoxic therapy
- T-scores 148, 149
- tamoxifen
 - and breast feeding 124
 - duration of treatment 125
 - endometrial cancer risk 159
 - gonadoprotection 46
 - interruption of treatment for pregnancy 123–4
 - and pregnancy 26
 - SOFT and TEXT studies 144, 147
 - vulval and vaginal actions 144
- taxanes, use during pregnancy 25, 26, 112–13
- termination of pregnancy
 - ethical issues 117–18
 - grounds for 117
- testicular cancer
 - azoospermia, fertility options 80
 - case studies
 - fertility preservation 78–81
 - in a gay man 177–80
 - effect on fertility 79
 - fertility preservation 13–15, 78–81
 - staging 178
 - subfertility rates 78–9
- testicular cryopreservation 102
- testicular dysgenesis syndrome 79
- testicular function, effects of chemotherapy and immunotherapy 154–5
- testicular sperm aspiration (TESA) 13, 101
- testicular sperm extraction (TESE) 13, 101, 153
 - in adolescent boys 102
 - case study 99
 - in post-treatment azoospermia 101
 - see also* micro TESE; onco-microTESE
- testosterone therapy
 - management in breast cancer patients 173–4
 - role in women 52
- TEXT study 144, 147
- thrombosis *see* venous thromboembolism
- thyroid cancer, pregnancy rates after therapy 3
- tibolone 51
- topoisomerase inhibitors, effect on testicular function 155
- trachelectomy 74
 - cervical stenosis 163–4
 - fertility and obstetric outcomes 74–5, 163
 - subsequent pregnancy 75
 - case study 162–5
- transgender men
 - breast cancer
 - androgen receptor positivity 172–3
 - case study 172–5
 - follow-up 173
 - specific challenges 175
 - surgical options 173
 - testosterone management 173
 - cervical screening 175
 - fertility options 174

- trastuzumab 112
 - effects on pregnancy 113
 - use during pregnancy 26
 - unexpected pregnancy 111–14
- tyrosine kinase inhibitors
 - breast feeding 27
 - use during pregnancy 25, 26–7, 117, 121
- ultrasonography 20, 120
- United States Childhood Cancer Survivors Study 3
- uterine bioengineering 48
- uterine transplantation 48
- uterus
 - haematometra 162, 164
 - intrauterine adhesions 164
 - radiotherapy damage 3, 127, 134
- vaginal dehydroepiandrosterone 52–3
- vaginal moisturisers 142
- vaginal oestrogens 142
 - use after oestrogen-sensitive cancers 52, 143
- vaginal symptoms of POI
 - case study 141–4
 - management options 142
 - and tamoxifen 144
- vasomotor symptoms
 - case study 141–4
 - management options 142–3
 - non-hormonal treatments 53
- venlafaxine 142–3
- venous thromboembolism (VTE)
 - association with HRT 138–9
 - case study 137–40
 - in hormone replacement therapy 39, 52
 - post-partum 84
 - during pregnancy 26, 27
 - prevention in pregnancy 139
 - risk factors for 138
- Virchow's triad 138
- vitamin D supplementation 40, 53
- vitrification 8, 65–6
- Von Hippel–Lindau syndrome 57
- welfare of child (WOC) assessment 61–2
- withdrawal bleeds 51
- Women's Health Initiative 39
- X-rays
 - fetal radiation exposure 20
 - during pregnancy 83, 120